| Overview |
| bs-1812R-Cy3 |
| Notch3/4 Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse Notch3 |
| 2001-2100/2318 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4854 |
| Nucleus, Cell membrane |
| hNotch 4;hNotch4;NOTCH 3;NOTCH3;INT 3;INT3;MGC74442;Neurogenic locus notch homolog protein 4;Neurogenic locus notch homolog protein 3;NOTC4_HUMAN;NOTCH-3;NOTCH-4;Notch 4 intracellular domain;Notch homolog 4;NOTCH4 protein;Neurogenic locus notch homolog protein 1; CADASIL; CASIL; Notch homolog 3. |
| NOTCH3 functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBP-J kappa and activates genes of the enhancer of split locus. It affects the implementation of differentiation, proliferation and apoptotic programs. Defects in NOTCH3 are associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (swissprot). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz